Candel Therapeuticsの空売り状況は、投資家がCandel Therapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Candel Therapeutics (NASDAQ:CADL) 株価情報, 空売り情報

Candel Therapeutics

Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Candel Therapeutics Inc

Cadeler AS

High-rolling investors have positioned themselves bullish on Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in BA often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 10 options trades for Boeing. This is not a typical pattern.
The sentiment among these major traders is split, with 60% bullish and 40% bearish. Among all the options we identified, there was one put, amounting to $227,500, and 9 calls, totaling $410,750.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $90.0 to $190.0 for Boeing over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Boeing's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Boeing's whale trades within a strike price range from $90.0 to $190.0 in the last 30 days. 
<h3>Boeing Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734015028_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$4.55</td>
<td>$4.35</td>
<td>$4.55</td>
<td>$170.00</td>
<td>$227.5K</td>
<td>1.8K</td>
<td>11</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$79.0</td>
<td>$78.05</td>
<td>$78.7</td>
<td>$90.00</td>
<td>$78.7K</td>
<td>35</td>
<td>10</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/27/24</td>
<td>$3.85</td>
<td>$3.6</td>
<td>$3.85</td>
<td>$170.00</td>
<td>$77.0K</td>
<td>2.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.85</td>
<td>$4.7</td>
<td>$4.7</td>
<td>$175.00</td>
<td>$51.7K</td>
<td>11.6K</td>
<td>133</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.5</td>
<td>$1.35</td>
<td>$1.51</td>
<td>$190.00</td>
<td>$39.8K</td>
<td>6.6K</td>
<td>1.0K</td>
</tr>
</tbody>
</table>

<h3>About Boeing</h3>
Boeing is a major aerospace and defense firm. It operates in three segments: commercial airplanes; defense, space, and security; and Global services. Boeing's commercial airplanes segment competes with Airbus in the production of aircraft that can carry more than 130 passengers. Boeing's defense, space, and security segment competes with Lockheed, Northrop, and several other firms to create military aircraft, satellites, and weaponry. Global services provides aftermarket support to airlines.
Having examined the options trading patterns of Boeing, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Boeing's Current Market Status</h3>
<ul>
<li>With a trading volume of 693,659, the price of BA is up by 0.04%, reaching $166.03.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 48 days from now.</li>
</ul>
<h3>Expert Opinions on Boeing</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $190.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Boeing, targeting a price of $190. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Boeing with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

A Closer Look at Boeing's Options Market Dynamics

Financial giants have made a conspicuous bearish move on Microsoft. Our analysis of options history for Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) revealed 30 unusual trades.
Delving into the details, we found 33% of traders were bullish, while 46% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $64,618, and 28 were calls, valued at $1,143,396.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $445.0 to $465.0 for Microsoft over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Microsoft's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Microsoft's whale activity within a strike price range from $445.0 to $465.0 in the last 30 days. 
<h3>Microsoft Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734015023_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSFT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/13/24</td>
<td>$4.95</td>
<td>$4.6</td>
<td>$4.79</td>
<td>$447.50</td>
<td>$96.5K</td>
<td>2.3K</td>
<td>264</td>
</tr>
<tr>
<td>MSFT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/27/24</td>
<td>$2.31</td>
<td>$2.3</td>
<td>$2.31</td>
<td>$465.00</td>
<td>$66.7K</td>
<td>21.1K</td>
<td>1.4K</td>
</tr>
<tr>
<td>MSFT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$2.67</td>
<td>$2.58</td>
<td>$2.67</td>
<td>$452.50</td>
<td>$60.4K</td>
<td>2.7K</td>
<td>2.8K</td>
</tr>
<tr>
<td>MSFT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$6.15</td>
<td>$5.7</td>
<td>$5.7</td>
<td>$447.50</td>
<td>$57.0K</td>
<td>2.3K</td>
<td>956</td>
</tr>
<tr>
<td>MSFT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$32.5</td>
<td>$32.2</td>
<td>$32.5</td>
<td>$465.00</td>
<td>$55.2K</td>
<td>28</td>
<td>20</td>
</tr>
</tbody>
</table>

<h3>About Microsoft</h3>
Microsoft develops and licenses consumer and enterprise software. It is known for its Windows operating systems and Office productivity suite. The company is organized into three equally sized broad segments: productivity and business processes (legacy Microsoft Office, cloud-based Office 365, Exchange, SharePoint, Skype, LinkedIn, Dynamics), intelligence cloud (infrastructure- and platform-as-a-service offerings Azure, Windows Server OS, SQL Server), and more personal computing (Windows Client, Xbox, Bing search, display advertising, and Surface laptops, tablets, and desktops).
Following our analysis of the options activities associated with Microsoft, we pivot to a closer look at the company's own performance.
<h3>Where Is Microsoft Standing Right Now?</h3>
<ul>
<li>With a volume of 1,309,255, the price of MSFT is up 0.68% at $452.05. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 47 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Microsoft, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

MSFT

Microsoft Unusual Options Activity For December 12

Investors with a lot of money to spend have taken a bearish stance on Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with WMT, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Walmart.
This isn't normal.
The overall sentiment of these big-money traders is split between 25% bullish and 50%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $93,440, and 6 are calls, for a total amount of $281,464.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $70.0 to $140.0 for Walmart during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Walmart's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Walmart's significant trades, within a strike price range of $70.0 to $140.0, over the past month.
<h3>Walmart 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734015018_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$25.4</td>
<td>$25.25</td>
<td>$25.28</td>
<td>$70.00</td>
<td>$126.4K</td>
<td>10.2K</td>
<td align="right">52</td>
</tr>
<tr>
<td>WMT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$47.35</td>
<td>$42.55</td>
<td>$44.71</td>
<td>$140.00</td>
<td>$67.0K</td>
<td>0</td>
<td align="right">15</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$5.2</td>
<td>$1.56</td>
<td>$4.0</td>
<td>$140.00</td>
<td>$40.0K</td>
<td>287</td>
<td align="right">0</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$1.89</td>
<td>$1.84</td>
<td>$1.86</td>
<td>$94.00</td>
<td>$31.9K</td>
<td>2.9K</td>
<td align="right">515</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$1.73</td>
<td>$1.7</td>
<td>$1.71</td>
<td>$94.00</td>
<td>$29.4K</td>
<td>2.9K</td>
<td align="right">694</td>
</tr>
</tbody>
</table>

<h3>About Walmart</h3>
Walmart serves as the preeminent retailer in the United States, with its strategy predicated on superior operating efficiency and offering the lowest priced goods to consumers to drive robust store traffic and product turnover. Walmart augmented its low-price business strategy by offering a convenient one-stop shopping destination with the opening of its first supercenter in 1988.Today, Walmart operates over 4,600 stores in the United States (5,200 including Sam's Club) and over 10,000 locations globally. Walmart generated over $440 billion in domestic namesake sales in fiscal 2024, with Sam's Club contributing another $86 billion to the company's top line. Internationally, Walmart generated $115 billion in sales. The retailer serves around 240 million customers globally each week.
After a thorough review of the options trading surrounding Walmart, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Walmart Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 364,928, the WMT's price is up by 0.7%, now at $95.62. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 68 days.</li>
</ul>
<h3>Professional Analyst Ratings for Walmart</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $98.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital has decided to maintain their Outperform rating on Walmart, which currently sits at a price target of $96. 
&#x2A; Maintaining their stance, an analyst from Guggenheim continues to hold a Buy rating for Walmart, targeting a price of $100. 
&#x2A; An analyst from TD Cowen has decided to maintain their Buy rating on Walmart, which currently sits at a price target of $100. 
&#x2A; An analyst from Keybanc persists with their Overweight rating on Walmart, maintaining a target price of $100. 
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Walmart, maintaining a target price of $96. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Walmart with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Decoding Walmart's Options Activity: What's the Big Picture?

HURA

The Cash Component Of The Aggregate Merger Consideration Will Be A Base Cash Amount Of $9,005,000 (Consisting Of A Value Of $15M Minus The $5,995,000 Advanced To Kineta Under The Exclusivity And Right Of First Offer Agreement)

CORRECTION: Bernstein analyst Gautam Chhugani reiterates MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) with a Outperform and maintains $600 price target. (Analyst firm corrected)

News

Price Target

Reiteration

Analyst Ratings

MSTR

CORRECTION: Bernstein Reiterates Outperform on MicroStrategy, Maintains $600 Price Target (Analyst firm corrected)

Wells Fargo analyst Edward Kelly maintains Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) with a Overweight and raises the price target from $70 to $73.

Wells Fargo Maintains Overweight on Kroger, Raises Price Target to $73

Trading Ideas

SFHG

Samfine Creation Holdings Shares Resumed Trade

Wells Fargo analyst Zachary Fadem maintains Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Overweight and raises the price target from $67 to $75.

Wells Fargo Maintains Overweight on Chipotle Mexican Grill, Raises Price Target to $75

APVO

Aptevo Therapeutics Inc. Shares Resumed Trade

On Thursday, Trevi Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) announced the outcome from the planned sample size re-estimation (SSRE) for the ongoing&nbsp;Phase&nbsp;2b&nbsp;CORAL trial&nbsp;in idiopathic pulmonary fibrosis (IPF) patients with chronic cough, which requires no change to the current <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/n42458078/trevi-therapeutics-announces-positive-outcome-from-sample-size-re-estimation-resulting-in-no-chang" rel="noreferrer noopener">sample size for the trial (N=160)</a>.
The CORAL trial is a double-blind, randomized, placebo-controlled, parallel-arm trial evaluating three doses of Haduvio (27mg, 54mg, and 108mg twice daily) compared to placebo in IPF patients with chronic cough.
The primary efficacy endpoint for the trial is the relative change in 24-hour cough frequency at the end of Week 6 versus baseline for Haduvio compared to placebo, as measured with an objective cough monitor (VitaloJAK). The trial will also explore secondary endpoints, including patient-reported outcome measures for cough.
The trial has reached 75% of the targeted enrollment,&nbsp;and topline results from the full trial continue to be expected in the first half of 2025.
The SSRE analysis was conducted on the highest dose (108mg twice daily) in the trial after 50% of the initial targeted trial enrollment, or 80 patients, completed the six weeks of treatment.
Based on the SSRE analysis, it was recommended that the CORAL trial should continue as planned to maintain the pre-specified conditional power of 80% or greater.
The other two potential pre-specified outcomes of the SSRE analysis were increased sample size or futility.
&#8220;We are pleased that the SSRE outcome supports the continued execution of the CORAL trial with the total number of patients as originally planned,&#8221; said&nbsp;Jennifer Good, President and CEO of Trevi Therapeutics. &#8220;This positive SSRE outcome is reassuring and confirms the key powering assumptions of the trial design. We believe this is additional confirmation of the strong efficacy observed in the Phase 2a CANAL trial in IPF cough&#8230;&#8221;
Price Action: At last check Thursday, TRVI stock was up 71.50% at $4.27.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42460099/us-listed-chinese-stocks-give-up-gains-in-anticipation-of-more-stimulus-to-beat-us-tariffs" target="_blank" rel="noreferrer noopener">US-Listed Chinese Stocks Give Up Gains In Anticipation Of More Stimulus</a></li>
</ul>

Biotech

Health Care

Movers

General

TRVI

Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?

Wells Fargo analyst Ike Boruchow maintains Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) with a Equal-Weight and raises the price target from $38 to $42.

BBWI

Wells Fargo Maintains Equal-Weight on Bath & Body Works, Raises Price Target to $42

WIIM

CELH

Celsius Holdings shares are trading higher after JP Morgan initiated coverage on the stock with an Overweight rating and a $37 price target.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Deutsche Bank analyst Steve Powers initiated coverage on Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) with a Hold rating and announced a price target of $81. Lamb Weston shares closed at $74.96 on Wednesday. <a href="https://www.benzinga.com/quote/LW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Oppenheimer analyst Kristen Owen initiated coverage on CF Industries Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) with an Outperform rating and announced a price target of $114. CF Industries shares closed at $89.82 on Wednesday. <a href="https://www.benzinga.com/quote/CF/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Michael Funk initiated coverage on Box, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) with a Buy rating and announced a price target of $40. Box shares closed at $32.27 on Wednesday. See how other analysts view this stock.</li>
<li>Macquarie analyst Steve Koenig initiated coverage on Autodesk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with an Outperform rating and announced a price target of $380. Autodesk shares closed at $307.46 on Wednesday. <a href="https://www.benzinga.com/quote/ADSK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Macquarie analyst Steve Koenig initiated coverage on MongoDB, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Neutral rating and announced a price target of $300. MongoDB shares closed at 297.20 on Wednesday. <a href="https://www.benzinga.com/quote/MDB/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ADSK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="622" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12094240/image-103-1024x622.png" alt="" class="wp-image-689605" style="width:612px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12094240/image-103-1024x622.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12094240/image-103-300x182.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12094240/image-103-768x467.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12094240/image-103.png 1083w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42437595/jim-cramer-says-keep-owning-this-energy-stock-abbott-laboratories-legal-stuff-is-behind-them">Jim Cramer Says &#8216;Keep Owning&#8217; This Energy Stock, Abbott Laboratories &#8216;Legal Stuff&#8217; Is Behind Them</a></li>
</ul>

Initiation

ADSK

This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Homebuyers should brace for another year of elevated mortgage rates, with Realtor.com forecasting an average of 6.3% next year. While down from 2024&#8217;s projected 6.7% average, rates will remain well above the 4% historical average from 2013 to 2019.
The silver lining is the expanding housing inventory, which Realtor.com projects to grow by 11.7% in 2025, according to the report. New construction will add to supply, with housing starts expected to jump 13.8% to 1.1 million units.&nbsp;
Don't Miss:
<ul>
<li>Unlock the hidden potential of commercial real estate —<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
<a href="https://www.benzinga.com/real-estate/reit/24/12/42316081/5-housing-market-trends-for-2025-what-zillows-forecast-means-for-you">After years of tight inventory</a>, the improvements could create more breathing room for buyers.
&#8220;This past year brought us a surprising upward trend in home price growth despite the persistence of high mortgage rates and rising inventory,&#8221; Realtor.com&#8217;s economists noted in their forecast. Home prices are expected to climb an additional 3.7% in 2025, following 2024&#8217;s projected 4% increase.
According to the forecast, the brief dip in mortgage rates to near 6% in September likely won&#8217;t return. &#8220;There will be volatility around this average, so shoppers may catch a lucky break, but our advice is to plan and budget for the mid-6% range.&#8221;
See Also: This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a>
Some markets already show signs of shifting power dynamics. About 20% <a href="https://www.benzinga.com/real-estate/24/10/41541572/purely-supply-demand-imbalance-5-u-s-cities-with-homes-still-under-300k">of listings nationwide had price reductions</a>, with Midwestern cities leading the trend. Cincinnati, Indianapolis and several markets across Ohio, Indiana and Illinois top the list for price cuts, led by Urbana, Ohio, where 71% of listings saw reductions.
Sales volume should tick up modestly, with existing home sales projected at 4.07 million – a 1.5% gain from this year but still well below the 2013-2019 average of 5.28 million. The report said that affordability challenges remain, though wage growth and tax adjustments could offer some relief.
Trending: During market downturns, investors are learning that unlike equities, these<a href="https://www.benzinga.com/money/connect-invest-real-estate-notes"> high-yield real estate notes that pay 7.5% &#8211; 9% are protected by resilient assets, buffering against losses.</a>
For renters, 2025 might bring slight relief. The Realtor.com forecast projects a 0.1% decrease in asking rents, continuing 2024&#8217;s 0.2% decline. New multifamily construction should boost supply, particularly in the South, where rental stock is expected to grow 1.5% annually – the highest regional rate nationwide.
&#8220;While the rental vacancy rate is at its highest level since the start of the pandemic, it remains somewhat below the 7.2% average seen from 2013 to 2019,&#8221; the report said, suggesting continued normalization of the rental market throughout the next year.
Read Next:
<ul>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>

Real Estate

'Plan And Budget For The Mid-6% Range': What Homebuyers Can Expect In 2025 According To Realtor.com

Vistra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) has outperformed the market over the past 5 years by 29.88% on an annualized basis producing an average annual return of 43.55%. Currently, Vistra has a market capitalization of $49.65 billion. 
Buying $1000 In VST: If an investor had bought $1000 of VST stock 5 years ago, it would be worth $6,020.01 today based on a price of $145.94 for VST at the time of writing.
<h3>Vistra's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734014712_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Wells Fargo analyst Eva Fortea Verdejo initiates coverage on Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) with a Overweight rating and announces Price Target of $37.

XNCR

Wells Fargo Initiates Coverage On Xencor with Overweight Rating, Announces Price Target of $37

Samfine Creation Holdings Group Shares Halted To The Downside, Stock Now Down -55.7%

Macquarie analyst Gautam Chhugani reiterates MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) with a Outperform and maintains $600 price target.

Macquarie Reiterates Outperform on MicroStrategy, Maintains $600 Price Target

Aptevo Therapeutics Shares Halted; Stock Now Up 23.4%

Chewy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) shares are trading lower Thursday after the company announced a public offering by a selling stockholder and a&nbsp;<a href="https://www.benzinga.com/pressreleases/24/12/b42448132/chewy-inc-announces-public-offering-of-class-a-common-stock-by-selling-stockholder-and-concurrent-" target="_blank" rel="noreferrer noopener">concurrent share repurchase</a>.
What To Know:&nbsp;Chewy announced an underwritten public offering of 15,852,886 shares&nbsp;of its common stock, being sold by an entity affiliated with Chewy's largest shareholder&nbsp;BC Partners Advisors. The selling stockholder plans to grant the underwriters a 30-day option to purchase up to an additional 2,377,932 shares of Chewy common stock. 
Chewy will not sell any shares in the offering, and will not receive any proceeds. 
In addition, Chewy has agreed to repurchase and retire $50 million of its common stock at the same price paid by the underwriters in the offering. The concurrent repurchase is being executed separately from the company&#8217;s existing $500 million share repurchase program that was authorized in May.
The offering comes after Chewy reported mixed quarterly results last week, beating on earnings but missing on revenue. The company guided for fourth-quarter revenue of $3.18 billion to $3.2 billion versus estimates of $3.17 billion.
Following the company&#8217;s quarterly results, Goldman Sachs lifted its&nbsp;<a href="https://www.benzinga.com/analyst-stock-ratings" target="_blank" rel="noreferrer noopener">price target</a>&nbsp;to $40, RBC Capital raised its target to $42 and JPMorgan maintained an Overweight rating and moved its price target up to $38.
Chewy shares are up approximately 37% year-to-date. The rally in the online pet retailer's stock accelerated over the summer after meme stock trader&nbsp;Keith Gill,&nbsp;also known as&nbsp;"Roaring Kitty,"&nbsp;announced a stake in the company. Gill has since announced that he <a href="https://www.benzinga.com/news/24/10/41614177/roaring-kitty-puts-chewy-stock-in-the-litter-box-gamestop-shares-move-higher-after-hours">sold his entire stake</a> in Chewy. 
See Also: <a href="https://www.benzinga.com/news/treasuries/24/12/42460477/producer-inflation-rises-more-than-expected-to-3-in-november-cast-shadow-on-further-disinflation-progress">Producer Inflation Rises More Than Expected To 3% In November: All Eyes On The Fed&#8217;s Interest Rate Call</a>
CHWY Price Action: <a href="http://benzinga.com/quote/chwy">Chewy shares</a> were down 2.8% at $31.63 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: courtesy of Chewy.

Offerings

CHWY

What's Going On With Chewy Stock Thursday?

Candel Therapeutics (CADL) announced preclinical results and therapeutic potential of CAN-3110 in the Ras-Raf pathway altered melanoma model. The d...

Candel Therapeutics to present data at SITC annual meeting on CAN-3110

"We remain on track for phase 2b and phase 3 topline data in non-metastatic, localized prostate cancer for CAN-2409 in the fourth quarter of 2024, ...

Candel Therapeutics reports Q3 EPS (33c) vs. (29c) last year

Cash and cash equivalents, as of September 30, 2024, were $16.6 million, as compared to $35.4 million as of December 31, 2023. Based on current pla...

Candel Therapeutics sees cash runway to end of 1Q25

Candel Therapeutics reports Q3 results

Vernon Bernardino, an analyst from H.C. Wainwright, reiterated the Buy rating on Candel Therapeutics (CADL – Research Report). The associated price...

Promising Potential of Candel Therapeutics' CAN-2409 Drives Buy Rating

Candel Therapeutics, Inc. ( ($CADL) ) has released its Q3 earnings. Here is a breakdown of the information Candel Therapeutics, Inc. presented to i...

Candel Therapeutics Advances in Cancer Trials Amid Financial Challenges

Candel stock rockets 130% on Phase 3 results for CAN-2409

Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Albertsons (ACI) terminated its merger...

Albertsons terminates Kroger deal, Macy's reports Q3 beat: Morning Buzz

Candel stock rockets on Phase 3 results for CAN-2409 (update)

ANAB

BLCO

CADL

CGNT

FIGS

IBRX

MDLZ

PDCO

PLAY

REVG

SFIX

SIRI

ULCC

VWAGY

VWAPY

Screenshot 2024-06-13 at 5.29.56 PM

Candel Therapeutics&#39; (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments

Screenshot 2024-06-06 at 5.30.54 PM

Candel Therapeutics&#39; (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers

Screenshot 2024-05-31 at 5.22.29 PM

Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer

Screenshot 2024-04-04 at 9.54.11 PM

Chief Science Officer Talks Innovation In Cancer Research

Screenshot 2024-03-25 at 6.13.53 PM

The CEO Of This Innovative BioPharma Is Bringing Light To Cancer Research

Screenshot 2024-03-14 at 5.26.26 PM

Candel Therapeutics (NASDAQ: CADL) Lead Product Candidate CAN-3110 Demonstrates Promise To Treat Deadly Brain Tumors

Screenshot 2024-03-05 at 6.31.45 PM

CGON

CLDI

TOVX

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Screenshot 2024-02-27 at 6.29.08 PM

Moving Fast: Candel&#39;s (NASDAQ: CADL) CAN-3110 Granted FDA Fast Track Designation For Recurrent High-Grade Glioma Following Fast Track Designation For CAN-2409 In Pancreatic Cancer

Small Cap

Press Releases

Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates

Earnings

Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Management

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting

Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)

Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma

Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024

Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

Comments

Candel Therapeutics

空売り

Candel Therapeutics (NASDAQ:CADL) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル